ArticleBipolar disorders2016

GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.

Carlos A Zarate et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.